Patent
Anorexigenic composition and method
Herbert Koppe,Gerhard Ludwig,Karl Zeille +2 more
- 28 Apr 1969
16
TL;DR: Anorexigenic compositions comprising a 1-phenyl-2-(lower alkylamino)-lower alkanone-(1) or a nontoxic acid addition salt thereof are an active ingredient, and a method of curbing the appetite of warmblooded animals therewith as discussed by the authors.
read more
Abstract: Anorexigenic compositions comprising a 1-phenyl-2-(lower alkylamino)-lower alkanone-(1) or a nontoxic acid addition salt thereof aS an active ingredient, and a method of curbing the appetite of warmblooded animals therewith.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Bupropion metabolites and methods of use
Thomas P. Jerussi,Mccullough John R,Chris H. Senanayake,Qun K. Fang +3 more
- 22 Feb 2000
TL;DR: In this article, the metabolites of bupropion were used for treating disorders ameliorated by inhibition of neuronal monoamine reuptake, such as cerebral function disorders, cigarette smoking, and incontinence.
57
Patent
Methods for treating obesity and weight gain using optically pure (-)-bupropion
James W. Young
- 28 Jan 1999
TL;DR: In this paper, the optically pure (-)-isomer of bupropion, which is a potent drug for treating obesity and weight gain, was used to treat obesity and obesity.
49
Patent
Pharmaceutically active morpholinol
Morgan Phillip Frederick,Musso David Lee,Partridge John Joseph +2 more
- 17 May 2002
TL;DR: In this article, the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them are disclosed.
47
Patent
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
James W. Young
- 22 Jun 1993
TL;DR: In this article, the optically pure (-) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines.
44
Patent
Bupropion metabolites and methods of their synthesis and use
Thomas P. Jerussi,Mccullough John R,Chrisantha H. Senanayake,Qun K. Fang +3 more
- 23 Aug 2000
TL;DR: In this paper, methods and compositions for using metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake have been presented, including, but not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence.
40
References
Patent
Preparation of alpha-alkylaminoacylophenones
Kamlet Jonas
- 27 Oct 1938
TL;DR: In this article, the preparation of alpha-alkylaminoacylophenones and particularly to compounds of the general formula C6H5.CHR.CO.NHR', where R represents hydrogen or an alkyl group and R' represents an alyl group.
7
Patent
Appetite-suppressing and weight reducing composition
Siemer Dr Harm
- 17 Sep 1962
TL;DR: In this article, a general formula for compounds of general formula where R is alkyl (1-3C), X is mono- or di-alkyl amino (the alkyls groups having 1-5 C), and Hal is halogen, also the compound 1-p-chlorophenyl-2-pyrrolidinopropan-1-one; their non-toxic salts; and their preparation by reacting corresponding a -bromo-alkanones with amines Pharmaceutical compositions comprise compounds of the invention and carriers forms described are
2